leisure time -WSS

leisure time

author：explore 2025-09-28 02:29:24 - browse：8371

Adam's take main illustration — Molly Ferguson/STAT

Shares of Apellis Pharmaceuticals are rebounding, driven by a growing belief among some investors that the serious safety issue that has derailed Syfovre, the company’s eye disease treatment, is receding.

Declaring the crisis over is premature, but that could change with more uneventful weeks. Apellis has been a takeout target before, and may be again, at an acquisition price nearly twice its current market value.

Apellis shares rose 32% last week, with most of the gains coming Friday on heavy trading volume. The reason: There have been no new cases of retinal occlusive vasculitis, or ROV, reported in people receiving injections of Syfovre.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Affirmative action in medical school literally saved lives
Next article： FTC sues over Novant Health acquisition of two N.C. hospitals

hotspot

WSS

10 reasons why health care startups fail

Making the case for fair compensation in clinical trials

Bernie Sanders is gearing up to subpoena pharma CEOs

Syphilis numbers in the United States reach record heights

At flashy new research hub, AstraZeneca lays out ambitious growth goals

FTC sues over Novant Health acquisition of two N.C. hospitals

focus

leisure time

explore

Cancer drug shortages should be causing more outrage

Eyeing GLP

In age of alternative facts, a scholarly course on calling out crap

FDA poised to publish guidelines for clinical trial diversity

The high cost of giving birth even with insurance

Why Medicare shouldn’t cover every FDA

What does generative AI mean for health care? We asked experts

Addressing health care workers' trauma can help fight burnout

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Cytokinetics CEO Robert Blum is on my Worst CEO shortlist again

leisure time

The Affordable Care Act has saved billions in health care costs

Eyeing GLP

Cytokinetics sells Royalty Pharma a share of its heart drug for up to $575M

Zyn nicotine pouches become unlikely player in latest culture war

Pancreatic cancer early detection could be helped by AI

Investigation reveals sickle cell patients pressured into sterilizations

explore

entertainment

hotspot

hotspot